THE WOODLANDS, Texas,
Nov. 3, 2011 /PRNewswire/ -- Lexicon
Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company
focused on discovering breakthrough treatments for human disease,
announced today that Dr. David
Powell, senior vice president of metabolism research, will
present data from clinical and preclinical studies of LX4211, a
dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and
SGLT2), at the Cambridge Healthtech Institute's Diabetes Drug
Discovery conference in Boston,
Massachusetts on Friday, November 4,
2011.
In clinical studies to date, LX4211 has demonstrated a favorable
safety profile and beneficial effects on multiple parameters of
glycemic control and cardiovascular health. Recent studies in
healthy subjects have shown that LX4211 substantially decreases
postprandial glucose levels without hypoglycemia and substantially
reduces triglycerides, results that have not been reported for
SGLT2-selective inhibitors. Data from a mechanistic study in
patients with type 2 diabetes demonstrated that a single dose of
LX4211 significantly increased circulating levels of GLP-1 (active
and total) and PYY, important regulators of glycemic and appetite
control. In addition, postprandial release of GLP-1 and PYY
from the gastrointestinal (GI) tract has been observed in
preclinical studies of SGLT1 knockout mice but not in SGLT2
knockout mice, indicating that inhibition of SGLT1 function may
trigger the postprandial release of these important regulators of
glycemic and appetite control.
For more information on this program or to download a copy of
the presentation, please visit www.lexpharma.com.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
breakthrough treatments for human disease. Lexicon currently
has four drug programs in mid-stage development for diabetes,
irritable bowel syndrome, carcinoid syndrome and rheumatoid
arthritis, all of which were discovered by Lexicon's research team.
Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has
focused drug discovery efforts on these biologically-validated
targets to create its extensive pipeline of clinical and
preclinical programs. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's clinical development of
LX4211, including characterizations of the results of and projected
timing of clinical trials of such compounds, and the potential
therapeutic and commercial potential of LX4211. This press
release also contains forward-looking statements relating to
Lexicon's growth and future operating results, discovery and
development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management's current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including those relating to Lexicon's ability to successfully
conduct clinical development of LX4211 and preclinical and clinical
development of its other potential drug candidates, advance
additional candidates into preclinical and clinical development,
obtain necessary regulatory approvals, achieve its operational
objectives, obtain patent protection for its discoveries and
establish strategic alliances, as well as additional factors
relating to manufacturing, intellectual property rights, and the
therapeutic or commercial value of its drug candidates, that may
cause Lexicon's actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Unless specifically indicated otherwise, results
reported as trends were not statistically significant. Information
identifying such important factors is contained under "Risk
Factors" in Lexicon's annual report on Form 10-K for the year ended
December 31, 2010, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.